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Abstract
Immunotherapy is an emergent form of cancer therapy that offers new and
innovative techniques that work to enhance the body’s natural ability to defend
itself against harm. This thesis seeks to explore the efficacy of vaccines that target
dendritic cells as one particular form of immunotherapy. Vaccination has the
potential to provide antigen (Ag) that is accessible to be processed by dendritic
cells, deliver the antigen to the dendritic cells, encourage dendritic cell maturation
and further promote the ability of dendritic cells to present antigen to effector cells
to encourage a tumor antigen-specific immune response. There are several different
elements in the process of achieving these ends including delivery of antigen to
dendritic cells in-vivo or ex-vivo, antigen selection, antigen-carrier use, addition of
adjuvants and the targeting of antigen to dendritic cells through soluble mediators.
These different components of dendritic cell-directed vaccinations will be detailed
and reviewed in order to understand the efficacy and immune-stimulating potential
of possible vaccines. Additionally, through a series of experiments, we were able to
determine that primed dendritic cells dramatically increased production of proinflammatory cytokines after micro-particle endocytosis. These preliminary tests
demonstrate that the tumor-Ag conjugated micro-particle matures dendritic cells to
promote and activate an immune response. The results of the experiments that were
performed and analysis of the various methods available for DC vaccination
indicates that this method of cancer therapy has extensive potential and requires
further testing to enhance efficacy and manufacturability of the vaccines.

Introduction
In the United States, over a woman’s lifetime, she has a 1 in 3 chance of
developing cancer. For men, this is a 1 in 2 chance [1]. Globally, 14 million people
are diagnosed with cancer and eight million people die from the disease each
year[2]. Despite the great strides that have been made in cancer research,
treatment, and long-term therapies, many patients still continue to develop
progressive, metastatic disease. At this point in time there are several different
methods of trying to combat and eliminate cancer cells in the body. Traditional
therapies include chemotherapy, radiotherapy, and surgical removal of tumors, but
a new and promising line of cancer therapies has emerged from the discipline of
immunotherapy. Immunotherapy seeks to harness the power of the immune
system and direct it to fight tumor cells. These therapies are often used concurrently
with traditional methods of treatment in order to maximize a patient’s response to
the therapy. These therapies are designed to elicit an immune response through
targeting specific antigens in the body (such as a tumor antigen), priming immune
cells to attack tumor cells selectively, trafficking appropriate immune cells to tumor
sites and neutralizing the immunosuppressive environment around the tumor cell
[3].
One type of immunotherapeutic approach involves vaccination. Cancer
vaccines are intended to encourage the body’s immune system to respond to
antigens that indicate the presence of an abnormal or cancerous cell. The immune
system recognizes a wide variety of antigens, which can be derived from exogenous
or endogenously expressed proteins. [4]. For example, antigens generated from

exogenous proteins are typically derived from pathogens including bacteria or
viruses. In contrast, endogenous proteins originate from within the body and
include normal self-proteins and those produced by abnormal or cancerous cells [4].
The goal of tumor-specific vaccination is to use antigens to activate cytotoxic T cells
capable of recognizing and responding to cancer-specific proteins. A promising
method of initiating this activation is known as dendritic cell vaccination. Dendritic
cells are a type of immune cell generated from the bone marrow that are critical in
initiating an immune response [3]. Dendritic cells do this by collecting antigens,
processing them and presenting them on their surface. This ability places them in a
category of cells known as antigen-presenting cells (APCs) [3]. In the vaccination
approach, dendritic cells are loaded with adjuvants that will cause maturation of the
cell as well as tumor antigens that will be presented by the dendritic cell to other
immune cells that will then locate and fight tumor-specific cells [5]. There have been
various studies using this approach to combat a variety of cancer types. These
studies will be reviewed and evaluated for their effectiveness in eliciting an immune
response through dendritic cell vaccination. In addition, we will discuss our studies
that used a tumor-specific antigen (SPAS-1) along with adjuvants in a dendritic cell
vaccination (DC vaccination) model in order to explore one possible way in which
DC vaccination could enhance the tumor-specific immune response.

Innate Immune System
The immune system is an integral part of the body’s survival mechanism that
evolved as the result of perpetual exposure to pathogens, organisms and foreign
molecules. The immune system functions as an interconnected network of organs,
cells and molecules that work to protect and repair the body. This system of
defense is divided into two sections, innate immunity and adaptive immunity. Both
of these systems operate in unique ways, but it is in their combined efforts that the
body is able to defend its self from viruses, diseases, parasites and even internal
threats such as cancer.
The innate immune system has developed from millions of years of evolution
and can be viewed as the elemental defense system. Innate immunity is the first
system to react once a pathogen has been detected in the body [6]. A pathogen can
be defined as any organism or agent that can cause disease. The innate immune
system is not pathogen specific; instead, it recognizes molecules that are found in
many pathogens, but are not found in the body [7]. These molecules are also known
as pathogen associated molecular patterns (PAMPs). Some of these stimulants
include molecules on the cell surface of the pathogen such as lipopolysaccharide
(LPS), teichoic acid, or bacterial flagella. PAMPs can also include short DNA
sequences such as CpG, which is an un-methylated repetition of the bases guanine
and cytosine [7]. Together PAMPs provoke the initial innate immune response.
There are several different cell types that function within the innate immune
system. One of these cells is the macrophage. Macrophages are derived from bloodborn monocytes. These cells are able to distinguish between “foreign” and “self”

molecules. This ability is crucial to protecting the body from attacking itself and thus
deterring autoimmune responses. Macrophages also have receptors for antibodies
and complement, which will be discussed in a further section. These receptors allow
for the cell to enhance its phagocytic abilities [6]. Through phagocytosis,
macrophages (and other phagocytic cells) can uptake, break down and destroy
pathogens. Eosinophils are another kind of immune cell. These cells function
primarily to protect the body from parasitic infections. These cells are not
phagocytic and rely on the release of cytokines and cationic proteins to kill foreign
invaders [6, 8] .
Natural Killer cells (NKs) are another group of cells within the innate
immune system that protect the body from pathogens and normal (self)-cells that
have been infected. NKs have many of the same morphological features of
lymphocytes, however they do not possess specific antigen receptors. Instead NKs
recognize abnormal or pathogenic cells through two different pathways. The first
pathway is through the use of immunoglobulin receptors (FcR). NKs can use these
receptors to bind to targets coated with antibodies. After binding to a target
pathogen, the NK is able to attack using antibody-dependent cellular cytotoxicity [8].
This method induces the cell to terminate itself via apoptosis. The second pathway
through which NK cells function in the innate immune system is through the
monitoring of MHC class I levels. These MHC proteins are expressed on almost
vertebrate cells. When an NK detects high levels of MHC proteins, it will not attack
the cell. However, when the NK observes low levels of MHC class I proteins, it is able
to selectively kill cells such as virally infected cells as well as cancer cells [7]. NKs

are extremely important to preventing viral replication as well as the expansion of
cancer cells.
Another cell type within the immune system that plays an important role as a
bridge between the innate and acquired immune system is the dendritic cell.
Dendritic cells are potent antigen-presenting cells that will be discussed in greater
detail in following sections. Dendritic cells are covered with a variety of receptors
including lipopolysaccharide receptors, mannose receptors as well as toll-like
receptors and several others. These receptors allow the cells to recognize antigens,
endogenous danger signals (such as those secreted by virally infected cells, or heatshock proteins resulting from necrotic cells) [6].
One of the first steps to occur within the innate immune system is the release
of cytokines from macrophages in what is known as an inflammatory response.
Macrophages are long-living immune cells that “patrol” tissues in the body and
engulf foreign pathogens through phagocytosis [7]. Cytokines are a group of soluble
proteins that help regulate cellular activity within the body, particularly the immune
system [6]. Once a macrophage has taken up a pathogen it becomes activated and
releases a series of cytokines including granulocyte (G-CSF) and granulocytemacrophage colony simulating factors (GM-CSF). These cytokines stimulate the
bone marrow to differentiate myeloid precursors into neutrophils, which are
subsequently released by the millions into the blood stream [8]. These neutrophils
are then recruited to the site of the invader and are able to uptake and kill the
pathogen or microorganism.

The complement system is another key part of the innate immune system.
The complement system is made up of a series of 20 proteins that are produced by
the liver and that circulate through the blood and the extracellular fluid. These
proteins are activated by both antibodies produced by B cells as well as by PAMPs to
attack the pathogens through lysis or by making them more susceptible to
phagocytosis [7]. The proteins within the complement system are activated in a
“cascade sequence” that has a self-amplifying effect, which reinforce its rapid and
destructive abilities. The complement proteins have limited pattern recognition
abilities allowing them to primarily target invading pathogens, however some cells,
such as resident microbes within the body can also be targeted by these proteins.
This sequence must promptly be deactivated in order to prevent the complement
proteins from attacking self-cells [7].
Aside from complement proteins, there are several other non-cellular
elements that function within the innate immune system. Many of these factors
serve as mediators, messengers and triggers that promote inflammatory responses,
complement cascade activation as well as immune cell activation and recruitment.
One such group of molecules is known as acute-phase proteins. The levels of these
proteins increase in response to infection and inflammation and they serve to
encourage tissue regeneration and promote resistance to infectious agents [6].
Cytokines are another group of soluble factors; they serve, for the most part,
as messengers both within the immune system and between the immune system
and other systems within the body [9]. Besides functioning as messengers, some
cytokines also have the ability to function directly within defense responses. Some

of these functional cytokines play important roles in mediating tumor resistance
and are increasingly being used as “therapeutic agents” in combination with
glycoproteins such as interferons.
Another group of molecules closely involved in communication is the group
known as adhesion molecules. These molecules are bound to the surface of immune
cells and facilitate information transmission between cells. These molecules are
critical in guiding movement of cells, promoting phagocytosis and regulating cellular
cytotoxicity [8]. These adhesion molecules, once attached to the cell surface can
encourage cell activation, cytokine production and promote the up-regulation of
surface receptors.
The functions of the adhesion molecules, like those of cytokines, complement
and acute-phase proteins are critical to enabling the immune system to recruit cells
to sites of inflammation, defend against malignant or infected cells, “warn” other
cells of the threat as well as promote a regenerative environment so that the body
can begin to heal itself.
Together, innate immune cells and non-cellular immune factors work
collectively to provide the first rapid response for defense against foreign pathogens
and malignant cells that are detrimental to the host. Innate immunity nondiscriminately safeguards the body. Its non-pathogen-specific design allows it to act
quickly and broadly and defend against a wide array of threats. While the processes
under innate immunity can be advantageous and useful in immune defense, in order
to create long-lasting and pathogen-specific responses, there must be collaboration
with the adaptive immune system. This collusion transpires largely through the

intermediary position of dendritic cells, which facilitate the cooperation of both
parts of the immune system.

Adaptive Immune System
While the innate immune system plays an important role as the first line of
defense against pathogens, the adaptive immune system, also known as the
acquired immune system, works to produce highly developed and targeted
responses. The innate immune system responds to the general presence of
pathogens, on the other hand, the adaptive immune system mounts responses to
specific pathogens encountered in the body. The adaptive immune system is
engaged only when the innate immune system detects the presence of PAMPs and
foreign Ag. This allows the immune system to develop specific responses only when
there is a genuine threat and not when there is merely a benign presence [9].
The adaptive immune system functions primarily through white blood cells
known as lymphocytes. Lymphocytes, which can be divided into two separate cell
types - B cells and T cells, develop within the bone marrow through processes
guided by stromal cells and cytokines [6]. B cells and T cells have antigen-specific
receptors, which empower them to produce their own unique immune responses. B
cells produce as antibody responses and T cells deliver cell-mediated immune
responses [9]. Following the presentation of antigen (Ag) to its respective antigenspecific lymphocyte, the T and B cells are primed, activated and differentiated into a
variety of effector cells with unique functions [8]. Together, B and T cells generate

pathogen-specific responses that allow for targeted, specific and long-lasting
defenses.
Antibody responses constitute one crucial component of the adaptive and
innate immune system. These responses are carried out by activated B-cells. In this
mechanism, B cells are signaled by other immune cells to secrete antibodies, which
belong to a group of glycoproteins known as immunoglobulins [9]. Antibodies are
composed of two main parts: two identical heavy chains, two identical light chains
[6]. At the N-terminal end of Ab, there are sites to which antigens can bind.
Antibodies have highly variable antigen-binding sites, which allows highly specific
recognition of unique antigens. This enables the antibody to “recognize” the antigen.
Antibodies serve several functions. They are able to activate complement, encourage
phagocytosis of bacteria, and bind to tumors and infected cells, which allows
effector and killer immune cells to target and attack the malignant cell [8]. Aside
from the functions of antibodies that have been released into the body by the
mature B cells, antibodies also play a key role in immature B cells. In the early stages
of B-cell development, antibodies are imbedded in the cell surface. Here, early
antibodies function primarily as receptor proteins that allow B-cells to capture
antigen and subsequently process it to present it via MHC class II surface molecules
to T-cells [8]. This process is similar to that which takes place in several other
immune cells known as Antigen Presenting Cells (APCs). Through these unique
functions of antibodies, B cells are able to contribute to both innate and adaptive
immune responses.

Once an antigen is expressed on the cell surface of a B-cell, it can be
presented to a particular subset of antigen-specific T cells. Just like B cells recognize
specific antigen via embedded surface antibody receptors, T cells carry unique
receptors designed to recognize distinct Ag presented by the B cell receptor. Once a
B-cell and a T-cell have combined recognition of the antigen, the T cell begins to
produce cytokines that promotes B-cell maturation, subsequently leading to the
antibody release previously described [6, 9].
While T-cells play a role in B-cell maturation/activation, they also serve a
variety of other functions within the adaptive immune system. Naïve T cells are, for
the most part, contained within the lymphoid tissue such as the spleen and lymph
nodes. Within the lymphatic system, the T cell will come in contact with an APC that
is presenting its antigen on the cell surface. This process is largely executed by
dendritic cells (DCs) that actively present antigen in the lymphoid tissues via MHC
class I or class II molecules. Other APCs include B cells and macrophages, each of
which promotes the T cell to develop and mature in unique ways. Once the T cell
interacts with the antigen, the T cell undergoes an activation period [8].
There are several different subclasses of T lymphocytes, which are
comprised largely of CD4+ and CD8+ cells. In their origins, T cells express both CD4
and CD8 co-receptors. During maturation in the thymus however, T lymphocytes
lose expression of one of the two co-receptors and consequently become selective to
the pathway of antigen recognition. These two emergent subclasses of T cells will
recognize antigen through different pathways and develop into effector cells with
unique abilities and functions [9, 10]. CD4 T cells only recognize antigen presented

via the MHC class II pathway, whereas CD8 T cells are uniquely able to respond to
antigen presented through MHC class I molecules [8]. MHC class I molecules
primarily function alert the immune system to the presence of virally infected cells
by presenting peptide fragments derived from self-proteins [11]. MHC class II
molecules, on the other hand, present antigen derived from exogenous sources [12].
In addition to stimulation via the MHC complex, T cells require costimulatory molecules to enable them to fully mature. TCR stimulation in the
absence of the appropriate co-stimulatory signals usually results in anergy or
apoptosis of the T lymphocyte. Dendritic cells (DCs) are one of the most effective
cells at promoting T cell activation as they are very efficient at Ag processing and
presentation and they express high levels of co-stimulatory molecules B7 and CD40.
[8]. Dendritic cells play a unique role within both the innate and adaptive immune
system and will be discussed in greater detail in the following section.
The innate immune system and the adaptive immune system, while utilizing
decidedly distinct methods of defending the body from harm, are only effective
through the inherent cooperation of both systems. These systems rely on
intercellular communication, cellular and non-cellular components and on complex,
interdependent pathways that work to defend the body against pathogens of all
sorts and, critical to this discussion, against host-borne malignancies such as cancer.
The immune system has the ability to defend itself against perpetual exposure to
foreign elements. The potential for cancer-defense is self evident in the potent and
effective design of the immune system. By understanding how and why the immune
system works, it is possible to harness its extant abilities and direct them towards

cancer cells. In the following section the importance and use of dendritic cells in
mediating the immune system will be illustrated.

Dendritic Cells
For decades the extent to which the immune system was able to uptake and
respond to external stimuli was not fully understood by immunologists and
biologists. Macrophages were viewed as the primary actors in the innate immune
system, however there was little evidence showing that macrophages linked the
innate to the adaptive immune system [13]. In 1973 Ralph Steinman’s discovery of
dendritic cells and subsequent research into their role in adaptive immunity forever
changed the understanding of the immune system and how it functions as a unit
rather than two separate entities. This discovery, which earned Steinman the 2011
Nobel Prize in Medicine of Physiology, is critical not only to understanding the
immune system, but also how to manipulate it for medical advancements [14].
Dendritic cells (DCs) serve a unique role within the immune system as they
function as a critical link between the innate and the adaptive immune system. DCs
are the most potent of the professional antigen presenting cells (APCs), which
include DCs, macrophages and certain B cells. In order to understand the extent to
which DCs function as a critical bridge within the immune system, it is important to
first understand DC biology, diversity and role in activating adaptive immune
responses.
Dendritic cells are a part of the body’s innate immune system. DCs are
derived in the bone from bone marrow-derived precursors and subsequently leave

through the blood stream as immature DCs and seed themselves into peripheral
tissues or directly in the lymph nodes [3, 15]. Immature DCs present in peripheral
blood and tissues are able to capture and uptake antigen (Ag) through several
integral processes (e.g. endocytosis and phagocytosis) [3, 14, 16]. Once a DC has
taken up and processed the antigen, it then undergoes maturation through the
direction of several cytokines [16]. In the maturation stage, the DC decreases its
ability to uptake antigens, and up-regulates its surface expression of MHC Class I
and MHC class II molecules, increasing the DC’s capacity to express the processed
antigen. Additionally, the DC up-regulates its expression of the chemokine receptor
CCR7, which allows it DC to migrate to a location where it can present antigen to Tcells [14].
After the uptake of Ag, the tissue-resident DC migrates to the draining lymph
nodes through afferent lymph vessel, which allow entry of cells into the lymph node
through all parts of its periphery [3]. Concurrently, the DCs process the Ag into
peptides, which are fragments of proteins, that then bind to and are presented on
the DC surface by MHC class I and MHC class II molecules. Once a DC has processed
the Ag and presented the ensuing peptide on the MHC complex, this complex is then
presented to naïve T cells in the lymph nodes and lymphoid tissues [14]. Naïve T
cells bind to the MHC-peptide complex and co-stimulatory molecules present on the
DC surface (e.g. CD80, CD86 and CD40), resulting in the activation and
differentiation of the T-cells. Typically, extracellular antigens such as bacteria,
parasites and toxins are presented via the MHC class II molecules and are presented
to CD4+ T cells. DCs present intracellular antigens including viral proteins and

tumor antigens expressed on MHC class I molecules to CD8+ T cells [14]. The
process through which DCs are able to take up exogenous proteins and present
them to CD8 T cells is known as cross-presentation. This aspect of DC antigen
presentation is critical to the understanding of the adaptive immune system and it’s
manipulation due to the fact that DCs are the only APCs that are able to present
extracellular antigens to CD8+ T-cells.

Figure 1. When immature DC come into contact with the correct combination of
antigen and maturation stimuli, the proceed to their mature, differentiated form and
are then able to process and present antigen via cross-presentation to T cells. This
figure was adapted from source #[17].

The location of uptake of Ag can lead to distinct responses by T-cells [3].
Lymph-node resident DCs acquire their antigen directly from the lymph and present
their peptides to naïve CD4+ T cells. In the presence of the appropriate stimuli (costimulation, etc) presentation of peptides results in T cell priming, and the
production of cytokines such as interleukin 2 (IL-2), which subsequently promotes
T cell proliferation and expansion. This process works conjunctively with the tissueresident DCs. The DCs that capture antigen in the peripheral tissues and

subsequently migrate to the lymph nodes to present their peptide already activated
CD4+ T cells, which, in turn, promotes the formation of effector T cells, particularly
CD4+ T helper cells [16, 18].

T-Cell Differentiation
The presentation of antigen to naïve T cells and their subsequent activation
is dependent upon several key chemical pathways and co-stimulation by the DCs.
Additionally, depending on the pathway, and the DC subset involved in the
activation process, T cells can differentiate into a variety of effector cells with
unique functions and abilities. As previously stated, DC up-regulate their costimulatory surface molecules, which interact with corresponding molecules on the
T cell surface to trigger its activation [16]. DCs also secrete cytokines, which
function to direct T cell differentiation. Naïve CD4+ T cells can differentiate into T
helper 1 cells (Th1), T helper 2 cells (Th2), T helper 17 cells (Th17) or T follicular
helper cells (Tfh) (and regulatory T cells). Th1 cells function as effector cells within
cell-mediate immune system that combats intracellular viruses and bacteria. These
cells also secrete cytokines which promote macrophage activation and cytotoxic T
cell production [19]. The Th1 subset of T cells secrete pro-inflammatory cytokines
that help to recruit cells such as neutrophils and macrophages to a site of
inflammation [20].Th2 cells are another variety of CD4+ effector T cell. Like Th1,
Th2 cells encourage production of B cells and macrophage activation. Additionally,
these cells have been associated with eosinophil and mast cell activation [21].
Finally, Tfh cells are critical in the formation of germinal centers, which are sites

located within the lymphatic system that promote B cell maturation and their
subsequent differentiation into plasma cells and memory B cells [22]. Naïve CD8 +
cells initially become effector cytotoxic T lymphocytes (CTLs) and then can further
differentiate into various subsets of memory cells, including central and effector
memory cells [3]. Each of these cells play a crucial role in immune responses and the
ability to shape how T cells differentiate is key to creating a successful immune
response against cancer cells.

Dendritic Cell Subsets
There are several different subsets of DCs and each subset has its own
unique function within the immune system. Human DC populations can be broken
down into two major subsets, plasmacytoid dendritic cells (pDCs) and myeloid
dendritic cells (mDCs), also known as conventional dendritic cells (cDCs) [23].
Plasmacytoid DCs are distinguished by their expression of the surface
molecule CD303+ and function primarily through the innate immune system. This
subset of DC is primarily found in the blood, thymus, bone marrow and lymph nodes
as well as other lymphoid organs. pDCs primary functions are to promote anti-viral
and anti-microbial innate immunity [14]. They do this primarily through the
secretion of type I interferons (IFNs) [23], which are a class of cytokine that can
initiate a rapid CD8+ T cell response and promote the “immunogenic maturation” of
other DC subsets [3]. pDCs are also capable of directing the transformation of
activated B cells into plasma cells [3]. There is some evidence that pDCs can

infiltrate tumors, however, there is still debate as to whether they play an antitumor role or whether they can promote tumor growth [14].
While the pDCs demonstrate limited utility in combatting tumors and tumor
growth, the mDCs show promise for use in cancer therapy due to the fact that they
have strong capabilities at processing and presenting antigen and thus activating
strong antigen-specific T cell responses. mDCs differentiate from myeloid
progenitors into several further subgroups. Some of these subgroups include
lymphoid tissue resident DCs, which include CD8+ DCs and CD8- DCs as well as
migratory DCs, which are the CD103+ DCs, CD11b+ DCs, epidermal Langerhans cells
and dermal interstitial cells [3, 23]. The lymphoid-tissue resident DCs arise from
precursors within the lymphatic system and are immature until stimulated by
antigen within the lymphoid organs. The migratory DCs differ in that they are
mature by the time that they reach the lymph [23].
One of the most important types of DCs in promoting an adaptive immune
response are the lymphoid tissue resident CD8+ DCs. This DC subset produces
particularly high levels of IL-12p70. IL-12p70 is an interleukin that stimulates the
production of interferon gamma (IFN-y) and tumor necrosis factor alpha (TNF-a),
which facilitates the differentiation of naïve CD4+ T cells into Th1 cells [24, 25].
Additionally, CD8+ DCs are highly competent at capturing and presenting exogenous
Ag via the MHC class I pathway to CD8+ T cells through cross-presentation [23].
These DCs are also proficient at capturing and processing dead or dying cells, which
makes them valuable in anti-tumor immunity efforts. By being able to take up and

process tumor cells combined with their strong ability to cross present, CD8+ DCs
are critical to initiating antigen specific T-cell responses against tumors.
While CD8+ DCs are highly capable of cross presentation through the MHC
class I pathway, CD8- DCs and the migratory DCs: CD11b+ DCs and Langerhans’
cells, play key roles in driving B cell responses and are more effective at presenting
antigen through MHC class II surface molecules. CD8- DCs and Langerhans’ cells are
superior mediators at antigen presentation via the MHC class II pathway [23].This
pathway, as discussed earlier, typically functions to active CD4 T cells. This is
evident in the ability of the migratory DCs to promote differentiation of naïve CD4+
T cells into Tfh-like cells [3]. These differentiated T cells are highly valuable in
promoting lasting immunity through the production of memory B cells. Another key
function of migratory DCs is their ability to shuttle Ag from where it was taken up to
a lymph node where it can “give” the Ag to a CD8a+ DCs, which are able to crosspresent with CD8+ T Cells [23]. The ability of the migratory DCs to donate their
antigen for presentation by other DCs combined with their own ability to cross
present Ag, allows for activation of both CD4+ and CD8+ T cells.
Maturation is a critical factor in DC directed immunity. Immature DCs are
effective at taking up Ag, however, antigen presentation by an immature DC is more
likely to induce immune tolerance to the Ag. Mature DCs, on the other hand, are
capable of inducing immunity through their particular ability to stimulate an
antigen specific T cell response coupled with their expression of potent costimulatory signals. DCs mature in response to exposure to “pathogens and their biproducts” [23]. Pathogens have certain unique signifiers that, combined with the

presence of an antigen, alert the DC to a threat and encourage the DC to mature in
order to be able to stage an immune response. Some of these signifiers come in the
form of pathogen-associated molecular patterns (PAMPs) and endogenous ligands.
These pathogen bi-products are recognized by DCs through the Toll-like receptors
(TLRs) on the cell surface. This leads to B7.1, B7.2 expression, IL-12 production,
and increased MHC expression on their surface, all of which help boost their ability
to stimulate naïve T cells in the lymph nodes. The ability to activate and promote
maturation and differentiation of DCs through adjuvants will be a critical concept in
the coming sections as this permits experimental manipulation of DCs and the
adaptive immune responses that they initiate.
Dendritic cells are powerful players within the immune system. They are
able to bridge the innate and adaptive immune systems to drive robust B and T cell
responses; it is through this dynamic that the immune system has the capability to
defend itself not only against foreign pathogens, but also from cancers originating
from within the body. The next sections of this article seek to evaluate two methods
of DC vaccination capable of enabling immune responses that fight against cancers:
ex-vivo (in-vitro) and in-vivo vaccinations.

Ex-vivo DC Vaccination
The immune system is capable of fighting a range of pathogens including
parasites, bacteria, and viruses. Through the systems in place designed to target and
destroy invading elements, there is the potential for the immune system to be able
to fight self-derived maladies, such as cancer. While the immune system can

eliminate early neoplastic cells that arise under normal conditions, once the cells
begin to multiply and mutate too quickly the immune system no longer has the
innate capacity to control the massing cells. In the beginning of a tumor growth,
there is a point at which the immune system wins out over the growing cells and is
able to eliminate them. In a second phase of tumor progression, there is a
equilibrium between the multiplication of the neoplastic cells and the rate at which
the immune system can destroy them. For these cells to progress to the point of
becoming a tumor, the immune system loses its control in a process known as tumor
“escape” [26]. One possible way of activating the immune system to combat cancer
cells once they reach the point of escape is by targeting dendritic cells through
vaccination.
Through vaccination, dendritic cells could be activated to help induce an
immune response that directly targets cancer cells. There are two broad categories
of DC-based vaccines: ex vivo and in vivo. Currently, Provenge (sipuleucel-t), is the
only DC-based vaccine that has been approved by the FDA. Provenge is an ex-vivo
generated vaccine that is used for patients with metastatic prostate cancer. The use
of this dc-based vaccine has demonstrated a 4-month median increase in survival
compared to patients’ treated with a placebo vaccine [14]. This success
demonstrates that the future of DC-vaccinations is conceivable and that through
proper research and development, full-scale vaccinations covering an array of
cancers could someday be viable treatment options. In the following sections, exvivo and in-vivo DC vaccinations will be discussed and evaluated for their efficacy,
their pragmatism, and their potential for inducing long-term cancer immunity.

Ex-vivo dendritic cell vaccinations are constructed by culturing
haematopoietic progenitor cells or monocytes with antigen and cytokines that are
able to induce DC maturation and increase their capacity to elicit tumor specific
immune responses [3]. These progenitor cells and monocytes are typically obtained
directly from the patient and as such, the preparation of ex-vivo vaccinations can be
labor intensive and expensive. On the other hand, the vaccinations can be precisely
tailored to the individual’s needs and unique situation. As previously mentioned,
there is only one FDA approved DC-based vaccine. There are several possible
explanations for why DC vaccinations have largely been thus far futile. Foremost, the
tumor microenvironment (TME) is highly successful at evading immune detection,
misdirecting immune cells, and inducing anergy among cells that are potentially
threatening to the tumor. Furthermore, to properly optimize dendritic cells to
enhance effective response, there are many different factors that must be taken into
consideration including: which kind of stimuli are used to activate the DC, which
kind of antigen to present and in what form, where and how many primed DCs
should be administered, how often and various other deliberations [14]. It is crucial
to understand these various elements of creating the vaccine in order to generate a
successful vaccine that is able to induce the immune system to directly target the
tumor and bypass the TME.

Figure 2. General Ex-Vivo Dendritic Cell Vaccination Strategy [27]: Ex-vivo derived
DC vaccinations depend on the collection of tumor antigens through either physical
collection or synthetic production. Subsequently the immature DC, typically a
monocyte or a haematopoietic progenitor cell, is presented with the tumor antigen,
which is then taken up by the DC through endocytosis. Finally, the DC is then
introduced to a series of cytokines intended to induce maturation and promote
expression of cell surface receptors integral to generating a targeted immune
response. This figure was adopted from source #[27].

Antigen Selection
One key element of priming a DC ex-vivo is selecting the type and form of
antigen to be captured and subsequently presented by the dendritic cell. Antigen
can be given to the dendritic cell in various forms including whole-purified tumorderived proteins, short peptides, cell lysate, tumor-derived RNA, or whole tumor
cells [28, 29]. The type of antigen delivered to the DCs could have dramatic
consequences in terms of how quickly the antigen is processed and presented, how

effective the antigen is at promoting an immune response or even whether or not
the antigen will induce an immunosuppressive responses that would hinder T-cell
effectiveness in attacking cancer cells.

Whole Tumor Cell Lysate
Whole tumor cell lysate is one of the many types of antigen sources and has
demonstrated relative success in a number of clinical trials. One example of the use
of whole tumor cell lysate supernatant as the source of antigen was in a study
looking at DC vaccinations targeting recurrent ovarian cancer [30]. In this study, six
patients underwent a series of treatments that began with intravenously
administered bevacizumab (anti-angiogenic drug) and orally administered
metronomic cyclophosphamide both of which function to inhibit angiogenesis. The
metronomic delivery method is one in which the patient receives continuous lowdoses of the drug, (i.e. once a day). This method is favorable in that it has
demonstrated lower levels of toxicity and it allows the drug to work progressively,
each administration compounding on the next [31]. Additionally, the lower doses of
cyclophosphamide have demonstrated preferential depletion of regulatory T cells,
which can inhibit anti-angiogenic progress. Next, the patients were vaccinated with
DCs that had been pulsed with autologous tumor cell lysate. Finally, the patients
were further injected with T-cells that had been previously exposed to the vaccine.
Out of the six patients treated, four demonstrated anti-tumor immune responses.
Overall, there was a 50 percent clinical benefit including a remission that lasted 14
months as well as one complete remission. While this treatment design

demonstrates a combinatory approach, it also suggests to a certain extent that DC
vaccination with tumor lysate as an antigen has the potential to promote anti-tumor
T-cell immune responses [30]. The researchers in this study discuss several
manners in which the treatment would be improved upon. First, the supernatants
used in this study were derived from “freeze-thawed” tumor lysates; the authors
suggest that using alternative techniques for obtaining the supernatants may have
yielded superior results. Secondly, the DCs were not matured with any additional
stimuli. The researchers also proposed that “stimulation with exogenous cytokines
and TLR agonists could significantly enhance vaccine potency” [30].

Peptides
Another promising category of antigen able to prime DCs is tumor specific
peptide fragments. These antigens are typically derived from tumor specific
proteins rather than self-proteins as to avoid an autoimmune response. They can
also, however promote targeting of over-expressed self-proteins like HER2 for
breast, PSA for prostate cancer that are expressed on the tumor. These proteins do
not activate T-cell responses in-vivo because the tumor cells lack the required costimulatory molecules[3, 29, 30]. One key benefit of using these peptide fragments is
that they are present in many patients sharing the same kind of cancer, making it
easier and cheaper to obtain and produce a vaccine that could benefit a large group
of people. Additionally, the peptide fragments that are associated with tumor
antigens can be created synthetically and uniformly allowing for a relatively cheap
means of production compared to using autologous cell lysate, which has to be

appropriated from each patient individually [32]. In a study performed by Nestle et
al., DCs were pulsed with several different tumor-derived peptides as well as
keyhole limpet hemocyanin (KLH), a type of large carrier protein, and delivered to
patients with melanoma. In this study, the peptide combinations used were tailored
to the particular patients’ haplotype, thereby maximizing the immune potential. The
vaccine was injected directly into the lymph nodes. Out of the 16 patients
participating in the trial, 11 demonstrated delayed-type hypersensitivity (DTH) to
the peptide pulsed DCs as well as peptide-specific CTL recruitment. Overall, three
patients manifested partial responses with regression of metastases and two
patients achieved complete remission [32, 33]. This study highlights several key
features about antigen selection for DC vaccination. First, an antigen, in this case
specifically a synthetically produced cancer-related peptide, that produces an strong
anti-tumor response in one individual, may not be ideal for another patient even one
with the same diagnosis. Tailoring antigen selection to an individuals’ particular
haplotype could provide a very valuable and effective treatment tool. This does,
however, require individualization, which as discussed earlier, can be labor
intensive and more extensive than a blanket treatment. Second, a combination of
tumor-associated peptides may be more effective than the use of one sole peptide.
This method provides the dendritic cell with the opportunity to deliver varied
antigen and signals to the effector cells thereby creating unique responses and
optimizing the potential for a successful immune reaction. Additionally, this method
of ex-vivo DC vaccination demonstrated no indication of autoimmunity or severe
reactions to the vaccine. This suggests that DC vaccination has the potential to be a

safe and less toxic form of treatment than chemotherapies and other kinds of cancer
treatments.
Another factor that must be taken into consideration when developing a DC
vaccination is the type of stimuli that must be added to encourage DC maturation
and specialization. Thus far, many studies have used a standardized set of cytokines
including TNF-a, IL-1B, IL-6, which are all pro-inflammatory and PGE2, which is a
cytokine shown to promote up-regulation of MHC molecules on the DC surface
molecules. While these cytokines have been successful to a degree at promoting DC
maturation, it has been suggested that this composition of cytokines fails to induce
IL-12p70 production and could potentially lead to the production of T-regulatory
cells. IL-12p70 is a key cytokine produced by DCs involved in encouraging the
differentiation of naïve T cells into Th1 cells [14]. A variation of this cytokine
cocktail involves the use of TNF-a, IL-1B, Poly(I:C), IFN-a and IFNy. This blend of
cytokines has shown to induce the IL-12 production that was lacking from the
effects of the preceding combination.
In a study performed by Stift et al., ten patients diagnosed with medullary
thyroid carcinoma (MTC) were administered an ex-vivo produced DC vaccination.
The dendritic cells were matured from peripheral blood monocytes that were
cultured with GM-CSF, IL-4, TNF-a and IFN-y and tumor lysate antigen. The
matured DCs expressed high levels of CD1a, CD11c, CD40, CD80, CD86, CD83 and
MHC II. This indicates that the DCs were effectively activated to promote T-cell
activation, differentiation and subsequent anti-tumor potency. In terms of clinical
effects, seven on the ten patients demonstrated prolonged tumor marker decline.

Three patients demonstrated a partial objective response, one patient exhibited a
minor response and two other patients demonstrated stable disease, thus no further
tumor progression. The researchers propose that TNF-a and IFN-y were critical to
encouraging the expression of co-stimulatory molecules on the dendritic cells, the
lack of which can lead to immune-tolerance [34]. The evidence presented in this
article suggests that the cytokines used in this study could be effective maturation
inducing agents. It is critical that the DCs not only be matured but also that they
have the necessary surface molecules to present antigens and to successfully
activate naive T and B cells through co-stimulation. For an ex-vivo derived
vaccination to be effective, these conditions along with careful antigen selection and
presentation must be met.
A final key consideration in the production and usage of ex-vivo DC
vaccination is the site of administration of the matured and primed DCs. So far, part
of the reason that DC vaccinations have had such limited clinical success is that once
the DC vaccine has been injected, the vaccine fails to migrate to the secondary
lymphoid organs[14]. Studies have demonstrated that less than 5% of injected DCs
typically reach the draining lymph nodes, which is a critical site for crosspresentation to T-cells [35]. In order to improve the migration of DCs, there are
several different possible measures that can be taken. First, the DC vaccine could be
administered at several different sites, thereby maximizing the odds that of
exposure to T-cells. Second, the DCs could be delivered directly into the lymph
nodes [14].

In-Vivo DC Vaccination
Ex-vivo stimulated DCs have demonstrated immense potential for use in
antigen-specific immune targeting through vaccination, however, the methods
employed to produce positive results can be time consuming, labor intensive and
extremely expensive. As an alternative, many researchers have turned to exploring
the possibilities of targeting DCs in-vivo. This process eliminates the necessity of
extracting and culturing autologous DCs, which can only be used for the individual
from which they were extricated. Additionally, it changes some of the challenges
that were presented with ex-vivo generation and delivery of the vaccine. For
example, a main concern with ex-vivo vaccination is the delivery site. The dendritic
cells must be injected into a location from which they can migrate. In-vivo
vaccinations, however, depend on the natural migration patterns of DCs from origin
to presentation of antigen to T and B cells. Under these circumstances, what
becomes most important is the delivery of the injected antigen to the DCs. Similarly
it is critical that the maturation cytokines contact the DCs to enable successful
mediation of antigen specific effector cell responses.
In order for an in-vivo DC vaccination to be successful, endogenous DCs must
be primed to present tumor antigens via both MHC Class I and MHC Class II
pathways so that both CD4+ and CD8+ T cells are engaged in anti-tumor immune
responses [14]. As with ex-vivo culturing of dendritic cells, there are several
different options for antigen sources. Tumor associated antigens can be produced
from oncogenic viruses such as HPV proteins, overexpressed variants such as
Her2/neu, which is a oncogene, or self-antigens that are overexpressed specifically

on tumors [14]. The up-regulation and high expression level of tumor proteins alone
is an essential defining factor in selecting a self-antigen in order to avoid an autoimmune response.
To enhance the probability of a directed and effective immune response in an
in-vivo DC vaccination, the chosen antigen must be successfully administered and
targeted to DCs in vivo. There are several different approaches currently being
tested to achieve this goal. The first involves the use of soluble mediating proteins
that interact with DC surface molecules [29]. In this model, the soluble mediators
are combined with the antigen and subsequently administered to the patient. These
mediators can play valuable roles in increasing not only the quantity of DCs, but also
the quantity of antigen that are presented and the migration of the matured DCs.
Several mediators that can be used to induce DC expansion and maturation in vivo
include fms-like tyrosine 3 kinase Flt3 ligand (Flt3L) and GM-CSF [29, 36]. These
mediators can also serve to cause differentiation of the DCs. GM-CSF generates
CD11b+ and CD8a-. With the addition of Flt3L, however, naïve DCs differentiate in to
CD11b+CD8a- and CD11b-CD8a+ DCs, each with unique priming and co-stimulatory
abilities [29]. Heat shock proteins (HSPs), another kind of soluble mediator, can
bind to DC surface receptors and induce DC maturation and promote presentation of
antigens via the MHC class I pathway. Cytosine phosphate guanosine
oligodeoxynucleotide (CpG ODN) is a particularly useful mediator that interacts
with TLR-9 on DCs and are particularly useful in priming pDCs to stimulate T-cells
[29, 36].

Particulate Antigen Delivery

Figure 3.. Representations of the different varieties of nano-particulate
particulate antigen
delivery systems;; this figure was adapted from source #
#[37].

Another method of antigen delivery involves the use of particulate vaccines.
Particulate vaccines have the benefits of long
long-term
term release of antigen, selective
antigen and adjuvant presentation, as well as the ability to target DCs specifically
spec
and even particular subgroups [38]. There are several different kinds of particulates
that can be used in vaccines. The first delivery system uses virus-like
like particles
(VLP). VLP are typically derived from viruses including Hepatitis B (HB) and
parvovirus (PPV).. These viruses, among others, have the ability to rearrange

themselves into particles that can encapsulate antigens [29]. Exposure to VLPs will
cause DCs to mature and secrete inflammatory cytokines [29, 39]. Additionally, VLP
can stimulate both CD4+ and CD8+ T cells in vivo. In several ways, VLPs are
particularly useful in that they act as both a carrier and an adjuvant. A key point to
acknowledge is that VLP are not infections and are thereby will not adversely affect
immune or other cells. The Hepatitis B VLP is particularly useful in protecting
antigen from deterioration. The HB VLP can be taken up by both macrophages and
DCs, which then present the delivered antigen via the MHC class I pathway. The
particles that sized in the range of 0.04-0.1 microns were, however, more effectively
taken up by CD205+DCs, while the larger VLPs were taken up by macrophages [40].
PPV-VLPs are taken up exclusively by CD8a- and CD8a+ DCs making them very
useful in solely targeting these DC subsets in vivo [29].

Synthetic Particles
Synthetic nano- and micro-particles are an example of a different type of
particulate that can be used to deliver antigen to DCs in vivo. In this design, antigens
can be conjugated to or encapsulated in synthetically created particles that can be
taken up by CD8a+ DCs and processed both in vivo and in vitro. One key advantage
to this approach is that there is greater flexibility for antigen selection, more
uniformity across particles, higher yield and increased stability than with the use of
VLPs or soluble mediating factors. There are two major categories of synthetic
particles that can be used; biodegradable and non-degradable.

Biodegradable Particles
Biodegradable particles are typically created from hydrolytically degradable
polyesters such as poly (D,L-lactic-coglycolic acid) copolymers (PLGA), poly (D,Llactide) (PLA), poly (ortho esters) (POE) or from liposomes or ISCOMs. Most of these
particles are not conjugated with danger signals and therefore do not produce
strong inflammatory side effects [29]. This makes the particle more tolerable to the
patients and potentially limiting the detrimental effects of the cancer therapy. PLGA
is a particular effective particle choice due to the fact that these particles have
demonstrated the ability to incorporate a wide variety of antigens, which makes
PLGA particles useful in a wide spectrum of cancers. PLGA particles are able to
protect the antigen from deterioration and they deliver the antigen to APCs, in
particular DCs, in a targeted manner. Typically, antigens by themselves have a
presentation time of approximately 12 hours by dendritic cells. In a study
performed by Shen et al., it was demonstrated the antigen delivered via PLGA
particles was effectively presented through the MHC Class I pathway for over 96
hours. This demonstrates the increased viability and stability of the antigens
introduced through this particulate system as well as the ability of these particles to
deliver antigen that targets CD8+ T-cell responses [41]. There is also evidence that
particulate antigens are more effectively utilized by DCs in cross-presentation and
activation of T cells [42]. PGLA particles also have the capacity to integrate and
deliver immune-modulators to DCs, such as TLR ligands, which can both encourage
DC immune capacity as well as reverse the effects of tumor-induced
immunosuppression of DCs [42]. Another benefit of using PLGA, is that is has been

approved by the FDA for the use of several different clinical application including
drug delivery [43]. This makes it a valuable material in terms of accessibility and
patient trials.
PLA and POE largely incorporate plasmids or tumor DNA as their primary
antigen. These delivery systems have been shown to be more successful at
producing antibody, CD4 and CD8 T cell immune responses than when DNA was
administered without a delivery system. PLA and POE protect the fragile DNA from
deterioration within the body. These systems, however, have limited antigen
selection capabilities making them useful only in certain types of cancer [29].
Liposomes, another type of antigen delivery system, are small phospholipid
vesicles that have been regularly utilized in vaccine designs. They, like the other
particles discussed, are able to encapsulate the selected antigen into their system
and deliver them to APCs. Liposomes are able to protect the antigens against
degeneration by the APC and thereby help to prolong the presentation time of the
antigen. This kind of delivery system helps to facilitate presentation of antigen via
the MHC class I pathway [29].
A fourth and final variety of biodegradable particles are immune-stimulatory
complexes, also known as ISCOMs. ISCOMs are spherical “cage-like” structures that
are composed of antigen, saponin, cholesterol and phospholipids [29, 44]. These
particles are highly immunogenic and are promptly and effectively endocytosed by
DCs. Delivery of antigen through the ISCOM particles, promote the presentation of
antigen through the MHC Class II pathway[29]. Studies have shown that ISCOMbased vaccines are highly effective at stimulating antibody responses in addition to

facilitating antigen specific CD4+ and CD8+ T cells, including CTL responses.
Additionally, these vaccines have demonstrated long-lasting immune responses,
which are critical for enduring tumor eradication [44]. ISCOMS have demonstrated
greater efficacy when combined with adjuvants such as LPS that contribute to DC
maturation and thereby the immune response[29]. Functionally, ISCOMS are best
suited to incorporate recombinant proteins [44].

Non-biodegradable particles
Non-biodegradable particles constitute the second kind of antigen delivery
system that can be created synthetically. Typically, these particles are made from
latex, gold, silica, iron or polystyrene. These particles are particularly useful in that
not only can antigen be incorporated on the surface of the structures, but they also
provide a surface to which adjuvants can be attached. Additionally, due to the nonbiodegradable nature of the particles, they endure inside the body allowing for
repeated exposure of antigens to DCs and therefore prolonged and recurrent
immune stimulation [37]. Another advantage of the use of non-biodegradable
particles is that their synthesis can be highly controlled and their size and shape can
be manipulated to meet the needs of the vaccine [37, 45]. Non-biodegradable
particles have demonstrated the ability to be engineered to present antigen highly
effectively through both MHC class I and class II pathways. These particles represent
one of the most customizable groups of antigen delivery systems. One of the most
favorable materials that have been used so far for the construction of nondegradable particles has been silica. Silica-based nanoparticles (SiNPs) are

biocompatible, effective at selective tumor targeting and are able to be monitored
in-vivo real time with multi-modal imaging [45]. Another key aspect of SiNPs is the
presence the silanol groups on the particle surface. These silanol groups can be used
to deliver a variety of molecules and adjuvants such as ligands, peptides and
antibodies. By using the silanol groups, the particles can be modified in ways that
allow for increased cellular recognition, increased efficacy at being taken up by
APCs, absorption of biomolecules, and higher ability to be directly targeted to cancer
cells [45, 46]. These factors that contribute to the effectiveness of the SiNPs as well
the other benefits discussed relating to non-biodegradable particles as a whole
demonstrates their potential for being a compelling antigen delivery system for DC
activation in-vivo. There is, however, some concern that because these particles will
not degrade naturally in the body, there is the potential for toxicity and
accumulation of particles within certain tissues [29]. In order to be certain that nonbiodegradable particles are safe for human treatment, these concerns must be
addressed and tested for optimal dosing and minimal toxic effects.

Figure 4. Antigenic Delivery by Nanoparticle: There are several different methods of
mediating antigen delivery through nanoparticle delivery. Antigens can be delivered
through conjugation, where they are chemically attached to the nanoparticle.
Encapsulation involves delivery of the antigen in which the antigen is enveloped
within the nanoparticle. Adsorption relies on a charge or hydrophobic interaction
between the particle and the antigen to connect the two. The final method of
introducing antigen and nanoparticles together in a vaccine relies simply on mixing
the two, without any direct interaction of the particle and the antigen [45]. This
figure was adopted from source [45].

Targeting DC Surface Molecules
Up to this point, we have primarily discussed methods of encapsulating or
securing selected antigens through various particles as a means of delivering it to
APCs, particularly DCs, in vivo. These methods are utilized to protect the antigen
from degradation, increase uptake by APCs, prolong antigen presentation time, and
increase the quantity of the selected antigen directed to DCs. Another aspect of

delivering antigen to DCs in vivo effectively involves targeting DC receptors
specifically. Several different adjuvants and antibodies specific to DC surface
receptors can be introduced either alongside or integrated into antigen delivery
particles in vaccines to increase their ability to selectively deliver antigen to DCs.
This is possible through the exploitation of the receptors present on the DC surface;
antibodies can be modified so that their variable region “fits” the DC receptors
similarly to how antibodies can selectively bind to antigens. Additionally, the ability
to target antigen to specific DC receptors consequently allows antigen and antigen
carriers to be targeted to different DC subsets, thereby tuning immune responses.
DC targeting can also be used to target antibodies, which instead of providing costimulation with antigen delivery directly, induce signals that aid in DC activation
and maturation [3].
Antigens are largely targeted to DCs through the use of DC surface lectins.
Many of these receptors belong to the C-type lectin receptor (CLR) family. CLRs
constitute a group of lectins that share a carbohydrate-recognition domain (CRD),
which allows them to bind to a select group of sugar residues. This aspect of CLRs is
valuable in that they can be present on the cell membrane and selectively bind to
passing sugar groups, connecting them to the DC. Several different CLRs that are
particularly useful for DC targeting include the mannose receptor, DEC-205 (also
known as CD-205), and DC-SIGN [36].
The mannose receptor is present on immature DCs. Targeting antigen to this
receptor increases antigen presentation via both the MHC class I and class II
pathways [36]. The mannose receptor can be targeted in vivo by fusing antigen to an

anti-mannose receptor monoclonal antibody (anti-MR mAb) [47]. These fused
complexes have been demonstrated to elicit both CD4+ and CD8+ antigen specific T
cells. Furthermore, MR targeted antigen vaccination strategies have shown to
promote anti-tumor responses [47].
DEC-205 is another type I CLR that is highly expressed on mature DCs and
largely functions to facilitate antigen presentation. DEC-205 is expressed in only
very low levels on other cells making it an ideal candidate for selectively targeting
DCs. In terms of research and trials, it is important to note that DEC-205 is
restricted to CD8+ DCs in mice, but it represented more widely in the human DC
population. This means that low level responses in the testing of mice, might not
necessarily reflect the response that would be exhibited in humans. Delivery of
antigen to DCs through the targeting of the DEC-205 receptor promotes CTL
responses as well as CD4+ T cells that provide prolonged induction humoral
immune responses [36]. A key point, however, in the targeting antigen to the DEC205 receptor, is that without proper stimulation with additional adjuvants, the DCs
could induce antigen specific tolerance in lieu of tumor specific immune responses
[48]. In order to avoid anergic responses, the antibody targeting DEC 205 (α-DEC205 Ab) should be administered in conjunction with adjuvants that induce DC
activation such as TLR3, TLR7 or CD40 agonists [48].
DC-SIGN is a surface receptor that is primarily expressed on immature
dendritic cells, and at lower levels on mature DCs. The antibody targeting the DCSIGN receptor effectively locates DCs that are present in the draining lymph nodes,
which is an ideal site for DC activation, stimulation and subsequent presentation of

antigen to the naïve T cells that settle in the lymph nodes [36]. This method of
targeting antigen to DCs has demonstrated that the presentation of antigen through
both MHC class I and II molecules and promotes memory T-cell, CD4+ T-cell, CD8+ T
cell as well as humoral responses leading to a multi-faceted and antigen specific
immune response. Currently, there is a clinical trial in progress examining the
effects of a DC-SIGN-targeted vaccine based upon the use as of a modified lentiviral
vector. Thus far, the use of the lentiviral vector in conjunction with the DC-SIGNtargeting approach has been shown to initiate aggressive anti-tumor T cell
responses [49].

SPAS-1 Conjugated Micro-particle Project
Several different methods have been described throughout this article as
possible ways to initiate and enhance immune responses against cancer cells
through the exploitation of dendritic cells’ natural abilities as antigen presenting
cells. Overall, the methods discussed have been designed to introduce dendritic cells
to a selected cancer-specific antigen and subsequently induce the presentation of
these antigens to immune effector cells. In order to further explore the potential and
efficacy of some of the approaches designed, we decided to test a possible
vaccination strategy utilizing iron micro-beads as a non-biodegradable antigen
carrier, SPAS-1 as the antigen, and several different adjuvants to promote DC
maturation and activation. The processes used to create these particles along with
tests performed to evaluate the ability of the micro-particles to affect DCs will be
detailed and assessed in the following sections.

SPAS-1 is a protein produced by the murine prostate cancer cell line TRAMPC1. SPAS-1 is a useful target for cancer therapy because it can be recognized by a
subset of tumor-specific CD8 T cells, it is upregulated by prostate cancer cells during
tumorigenesis and it is not expressed on normal cells. This means that SPAS-1 can
be targeted effectively by the immune system and that it will not promote
autoimmune immune responses. In order to elicit an immune response against the
SPAS-1 antigen, we examined the effects of using a micro-particle vaccine containing
the SPAS-1 antigen combined with lipopolysaccharide (LPS), CL264, and αDEC-205.
Lipopolysaccharide (LPS) is a molecule found on the outer membrane of some
bacteria. It is a one of the pathogen associated molecular patterns (PAMPs) that can
be recognized by immune cells with pattern recognition receptors (PRRs). When
encountered by macrophages, dendritic cells or some B-cells it elicits a strong
immune response encouraging these cells to secrete pro-inflammatory cytokines.
CL264 (in this case biotin labeled) is a ligand that promotes dendritic cells to secrete
the pro-inflammatory molecule interferon-alpha (IFN-α) and to activate the NF-κB
pathway. NF-κB is a protein that is critical in regulating genes and up-regulating
genes that are involved in T-cell development, maturation and proliferation. These
proteins are able to activate immune cells to respond to the presence of the tumor.
αDEC-205, the antibody that binds to DEC-205, was used as the DC targeting
antibody.
The micro-particles were created and tested for efficacy through
administration to DCs in-vitro, however, the end goal of this particle was in vivo

antigen delivery to and subsequent activation of DCs in order to prime tumor Agspecific CD8 T cells.

SPAS-1 Purification
The first step in the process of creating the micro-particle was to obtain a
purified version of the SPAS-1 protein that could be used as an effective antigen. In
this study, the SPAS-1 protein was derived from a 6xhistag-GFP-(green florescent
protein) tagged SPAS-1 recombinant E. coli. To separate the GFP-tagged SPAS-1
from the E.coli, the recombinant specimen was subjected to a series of buffer
combinations aimed at solubilizing the SPAS-1 protein, thereby separating it from
the E. coli. The most effective buffer cocktail consisted 100µL base solution (10mM
Imidazole, 50mM Sodium Phosphate, 5mM arginine and 0.01% tween 20 in 200mL
distilled water), 125µL 2M Urea, 125µL 750mM NaCl, and 25µL 0.1% Triton. The
solubilizing solutions were evaluated for their ability to separate the soluble from
the insoluble portions of the recombinant E. coli. Due to the fact that the
recombinant E. coli was GFP-tagged, the relative fluorescent intensities of both the
soluble as well as the insoluble portions were able to be determined through the
examination of the portions using a using a 510-590 wavelength filter. The soluble
to insoluble fraction ratio was determined using the fluorescent intensities for each
buffer solution. The buffer solution that produced the highest yield of the soluble
portion (i.e. the SPAS-1) relative to the insoluble portion was selected as the most
effective buffer solution.

In order to continue purifying the remaining SPAS-1 recombinant E. coli, the
recombinant E. coli was subjected to the optimal solubilizing solution. The mixture
was then run through a centrifuge, separating the soluble and insoluble fractions.
Next off, the soluble fraction was filtered through a three filter series of 1.2µ, 0.45µ
and 0.2µ filters. This process resulted in approximately a 50% SPAS-1 protein
extraction efficiency when compared to the amount of SPAS-1 present in the
original recombinant solution.
The filtered solubilized SPAS-1 solution was then further purified from
background materials that were not removed through the preliminary extraction of
the SPAS-1 protein from the SPAS-1 recombinant E. coli. This was achieved by using
the “Akta Pure” which uses the Nickel affinity purification process. First the SPAS-1
protein solution was run through the purification column. This was followed by a
load binding/ wash buffer consisting of 10mM Imidazole, 50mM Sodium Phosphate,
5mM Arginine, 2M Urea, 0.01% Tween-20, 2M Urea and 0.1% Triton x-100 in
ddH2O. This wash buffer was used to wash away anything that was not sticking to
the nickel column. After this, an elution buffer (made of 250mM Imidazole, 50mM
Sodium Phosphate, 1.5M Sodium Chloride and 5mM Arginine in ddH2O and 0.5M
NaOH) was run through the column and the flow-through was collected. The elution
buffer functions to strip the column of the target SPAS-1 protein. Next, the elution
buffer was run through once again. A slightly altered version of the elution buffer
was then run through the column, in which the concentration of Imidazole was
increased to 500mM and concentration of Sodium Chloride was increased to 2M.
These runs were followed by another wash flow-through, an elution flow through, a

NaCL flow through and finally a Nickel solution flow through. The collected flow
through samples were then examined for their levels of fluorescence.
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Figure 5. Average MFI of Products of SPAS-1 Purification Process

The collected samples and their respective mean fluorescent intensities
(MFIs) demonstrated that the flow through from the primary elution yielded the
highest level of purified SPAS-1. The results demonstrated that the Elution #1
yielded the highest concentration of the SPAS-1 protein. This elution, along with the
third elution run through were subsequently concentrated for use in the following
experiment.
In order to examine the progression of the purification throughout the
varying purification steps and to estimate the final yield of the SPAS-1 protein, the
solutions present through the various stages of protein purification were run

through the Thermal Cycler and subsequently added into nine different wells of the
gel for a SDS-PAGE (sodium
sodium-dodecyl sulfate poly-acrylamide
acrylamide gel electrophoresis)
electrophoresis
test. In order to be able to examine the results, dye was added to stain the proteins
present in the gel and the gel was imaged. The following stages of protein
purification were added to the wells in their respective orders: 1) insoluble SPAS-1
SPAS
Recombinant E. Coli 2) Soluble SPAS
SPAS-1
1 Protein 3) Soluble and Filtered SPAS-1
SPAS
Protein 4) Purification Binding Flow
Flow-through 5) Purification wash flow-through
through #2
6) Elution #1 7) Elution #3 8) Concentrated Elution #1 9) Concentration Elution #3.

SPAS-1 Protein

Figure 6. 3-D
D Representation of SDS
SDS-PAGE
PAGE results on varying stages of SPAS-1
SPAS
purification process

SPAS-1
1
In well number two,, we can see that the original insoluble SPAS
recombinant E. coli
oli has a large amount of many different proteins in it. As the
purification process progresses, the amount and variation of the proteins decreases
decr

until we are leftt primarily with our target protein, which is shown in the number 9
sample which was a concentrated version of elution #1. It was surprising to see that
the concentrated elution 1 was very similar to the well number four which
represents the filtered solub
soluble SPAS-1
1 solution. This shows that the nickel affinity
purification process was not as successful as we might have hoped. This gel does
however show us the yield of the SPAS
SPAS-1
1 protein from the purification process. Well
1 represents the standards column ffrom
rom which other levels of proteins can be
determined. We compared the amount of SPAS
SPAS-1
1 protein in well 9 to the control in
well 1 and we can see that we have approximately 500ng of the protein in 20µL (or
~25ng/µL) of the concentrated elution solution #1.

6xHistagscGFP-SPAS-1
Recombinant
E. Coli

Solubilized
SPAS-1
1
Solution

Filtered
Solubilized
SPAS-1
Solution

Figure 7. Overall SPAS-1
1 Purification Process

Partially
Purified SPAS1 Solution

Purified SPAS1 Attached to
Micro-Particle

Micro-Particle Production
Next, we created a variety of micro-particles and determined the relative
amount of antigen and antibody bound to the micro-bead. Iron-oxide micro-beads
with streptavidin were used as a form of non-biodegradable antigen carrying microparticle. We used a tumor-specific antigen (SPAS-1) plus LPS, CL264 and αDEC-205.
The combination all the adjuvants on a micro-bead creates what are called dendritic
cell activating receptor-targeted particles (or DARTs). The iron-oxide micro-beads
were covered in streptavidin molecules. Streptavidin has an extremely high affinity
for biotin. In order to determine the most effective micro-particle we created five
different variations. The variations were as follows: 1) iron-oxide beads + LPS, 2)
beads + CL264, 3) beads + αDEC-204, 4) beads + SPAS-1, 5) DARTS + SPAS-1.
In order to connect the αDEC-205 to the micro-bead, we had to add an antirat secondary antibody with a biotin molecule that could bind to the bead. Because
the αDEC-205 used in this experiment is a rat antibody it connects to the anti-rat
secondary antibody. The SPAS-1 requires an additional step. First, an anti-rabbit
secondary antibody, which has a biotin molecule, connects to the streptavidin
molecule. Second, an anti-6x-histag of rabbit origin connects to the secondary
antibody. Third, because the SPAS-1 antigen was created with a 6x-poly-histidine
tag, it can be added and connect to the anti-6x-histag.

.
Micro-Particle
Particle Assembly: This image is depicts a DARTs +
Figure 8.. Example of Micro
SPAS-1 micro-particle arrangement in which all of the adjuvants as well as the SPASSPAS
1 antigen have been conjugated to the iron
iron-oxide micro-bead
bead through the
streptavidin molecule and a series of binding antibodies.

Figure 9. Image of DC2.4 Dendritic Cells with DARTs + SPAS
SPAS-1 Particles

Because the αDEC-205 and SPAS-1 antigen contain a fluorescent tag, the
amount retained on the micro-particle can be tracked. Known amounts of αDEC-205
antibody and SPAS-1 antigen were added to the micro-particle. After washing, the
particles the amount of SPAS-1 and αDEC-205 that were retained on the microparticles was determined. For the beads + αDEC-205, approximately 11% was
retained after the wash. For the DARTS and the added αDEC-205 only 4% was
retained. There were approximately 22,000 αDEC-205 molecules on the beads +
αDEC-205 microparticle and only 8,000 on the DARTS + SPAS-1 molecule. This is
likely due to the competition for space on the DARTS particle. On the DARTS there is
not only αDEC-205 but LPS and CL264 as well. On just the beads, the SPAS-1 antigen
was retained at 17.1% after the wash and on the DARTS 16.8% remained attached.
We determined that there were approximately 25,000 SPAS-1 molecules per ironoxide micro-bead for both the beads + SPAS-1 micro particle as well as the DARTS +
SPAS-1 molecule. These higher numbers indicate strong bonds allowing the SPAS-1
to securely attach to the micro-particle.
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Figure 10. Mean Fluorescent Intensity of αDEC-205 before and after wash
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Figure 11. Mean Fluorescent Intensity of SPAS-1 on Beads before and after wash.
Figures 11 and 12. Figure 10 depicts the mean fluorescent intensity of 12 wells of
the αDEC-205 before and after wash per condition. Figure 11 depicts the mean
fluorescent intensity of 12 wells of SPAS-1 per eight conditions shown above.

Micro-particle Testing
In order to determine the relative effectiveness of the engineered microparticles, several different tests were performed to examine the ability of the microparticles to be taken up and processed by DC2.4 dendritic cells and thus induce an
immune response. The first test performed was an immunocytochemical test, which
was used to assess the expression of CD40, CD86, MHC Class I and MHC Class II
molecules on dendritic cells after exposure to the different micro-particles. The
dendritic cells exposed to the micro-particles were incubated with fluorescently
tagged anti-CD40, anti-CD86 and anti-MHC Class I/II antibodies. (Approximately ##
hours or min later), the dendritic cells were scanned to determine the expression of
the indicated surface molecules.

Figure 12.. Fluorescence of Treated Dendritic Cell: Columns 1
1-3
3 contain DCs treated
with nothing. Columns #4--6 depict CD40, #7-9 CD86 (B7.2), and #10--12 MHC I/II
expression. DC2.4 cells were treated with
with: A) nothing (media), B) beads only,
only C)
beads + LPS, D) Beads + CL264
CL264, E) Beads + DEC-205, F) Beads + SPAS-1,, G) DARTs +
SPAS-1.

For this experiment w
wee focused on four surface receptors: CD40, CD86, major
histocompatibility complex (MHC) class I and MHC class II molecules. These
hese surface
receptors are essential components for provoking an immune response and
activating T cells. Thus, their up
up-regulation
regulation as a result of exposure to the micromicro
particles would demonstrate that the particles ar
aree successfully priming the
dendritic cells to activate T cells.
The beads + LPS treatment demonstrated the most up
up-regulation
regulation of the
target surface receptors in the dendritic cells. CD40 expression was increased 60%

over baseline expression, CD86 was increased over 40%, MHC class I expression
increased over 30% and MHC class II expression increased by over 200% over the
baseline expression in untreated dendritic cells. All of the treatments besides the
beads only treatment demonstrated increased levels of surface receptors. However,
we observed significant experimental variation, thus these data need to be repeated
to ensure the results are consistent. We believe that much of this error is a result of
the timeframe in which the experiment was done. The expression levels were read
approximately 24 hours after the dendritic cells were exposed to the microparticles. It is possible that had the cells been able to incubate longer with the
particles, there may have been less error in the readings and a more accurate
representation of the levels surface receptor expression.
The next test performed was an enzyme-linked immunosorbent assay
(ELISA) that was used to test for production of the cytokines TNF-alpha and IL-6.
The ELISA was performed as dictated by the eBioscience ELISA kit.
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Figure 13. Concentration of IL-6 Secreted by Dendritic Cells after Treatment: Mean
concentration of IL-6 secretion of eight wells per treatment.
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Figure 14. Concentration of IL-6 Secreted By Dendritic Cells After Treatment: Mean
concentration of TNF-α secretion of eight wells per treatment.

In the previous experiment, we were looking at the surface receptors being
expressed by dendritic cells after exposure to the micro-particles described in
experiment 5. In this experiment, we are looking at what cytokines the dendritic
cells secrete to determine how these treatments affect DC polarization. To do this
we looked at two cytokines, IL-6 and TNF-α. IL-6 is a cytokine that is involved in
promoting inflammation and in the maturation and differentiation of B cells. Tumor
Necrosis Factor Alpha (TNF-α) is an inflammatory cytokine involved in tumor
necrosis, inhibition of tumorigenesis, neutrophil proliferation and apoptosis. The

increased production of these cytokines by a dendritic cell indicates that the
dendritic cell has recognized a potential threat and is promoting an immune
response against that threat.
We established baseline levels of IL-6 and TNF-α being produced by
dendritic cells. These dendritic cells produce an average of 0.33ng/mL of IL-6 and
0.35ng/mL TNF-α. The IL-6 ELISA shows that dendritic cells exposed to beads +
LPS, beads + DEC-205 demonstrate a slight increase, while the cells exposed to
beads + SPAS-1 and DARTS + SPAS-1 secrete over 9 times the amount of IL-6 than
the untreated cells. This suggests that while LPS and DEC-205 can influence a
dendritic to secrete IL-6, exposure to a specific antigen drives a more extreme
response. Furthermore, the combination of the antigen with the DARTS complex
drives an even slightly higher concentration of IL-6. This suggests that the
combination of antigens and adjuvants is the most successful at encouraging
dendritic cells to secrete IL-6.
In the TNF-α ELISA, the beads + LPS, beads + SPAS-1 and DARTS + SPAS-1 all
show highly increase concentrations of TNF-α. The LPS treatment results in a TNF-α
concentration of 1.46ng/mL, the beads + SPAS-1 treatment a concentration of
2.27ng/mL and the DARTs + SPAS-1 treatment a concentration of 2.38ng/mL. The
beads + CL264 treatments shows a small increase while the beads only and beads +
DEC-205 treatments have almost no effect on TNF-α secretion. These results
suggest that the LPS, which has a pathogen-associated molecular pattern, and the
SPAS-1 antigen have the most effect on the dendritic cells, the combination of which
drives the highest response and thus the highest concentration of secreted TNF-α.

Conclusions
Overall this project has illustrated several key promising features of
dendritic cell vaccinations and it has also identified several areas that could be
improved upon and re-worked for stronger anti-tumor immune responses.
When exposed to the micro-particles, the beads + LPS micro-particles demonstrated
the highest level of up-regulation of cell surface receptors including CD86, CD40,
MHC Class I and MHC Class II molecules. The DARTs + SPAS-1 micro-particle only
demonstrated up-regulation of CD86 and MHC Class II molecules over the baseline.
As discussed previously, it is possible that a prolonged incubation period could lead
to different results, however the results do indicate interesting aspects of dendritic
cell activation. First, LPS is a PAMP, which was used in this experiment to instigate a
strong immune response in the dendritic cells. It is evident that this was true in the
case of the up-regulation of cell-surface receptors. It is interesting that there was
significantly less prevalence of the surface receptors when the dendritic cells were
exposed to the DARTs + SPAS-1 micro-particle. This indicates that due to the
competition for space on the micro-bead, less LPS was attached to the micro-particle
and therefore we did not see as strong of response. Additionally, it indicates that the
SPAS-1 antigen had little to no effect on inducing an up-regulation in surface
receptors on the DCs.
While the cell surface receptors were not highly impacted by the DARTs+
SPAS-1 micro-particles, the cytokine production demonstrated significantly higher
levels of secretion by dendritic cells that were exposed to the beads + SPAS-1, and
even more so by the DARTs+SPAS-1 micro-particles. These results indicate that the

SPAS-1 antigen plays a crucial role in promoting cytokine secretion by the DCs.
Additionally, the results show that the addition of the adjuvants further promote
this function.
While this was just one study used to examine the effects of antigen and
adjuvants through a micro-bead delivery system on dendritic cell function, there are
several different things that could be improved upon in subsequent testing. First,
while the purification process was relatively effective in singling out the SPAS-1
antigen, as can be seen in Figure 6, there are still other proteins present in the
solubilized solution that was created. A purer form of SPAS-1 may result in better
results and stronger DC responses. Furthermore, as described in previous sections,
the use of non-biodegradable antigen delivery systems has several benefits, but
these particles also have the potential to have toxic side effects, build up in the
tissues as well as limited re-vaccination potential. The use of a biodegradable
antigen carrier such as a PLGA or ISCOM micro-particle could have the same
immunogenic effects without some of the concerns relating to non-biodegradable
systems. Finally, it may also be beneficial to tinker with different combinations of
adjuvants in order to determine the optimal combination for maturing DCs,
increasing DC surface receptor expression and promoting cytokine secretion, all of
which are crucial to antigen presentation, T-cell activation and differentiation and
an overall stronger anti-tumor immune response.

Summary
Cancer therapy has taken considerable strides in the past years. The
introduction of immunotherapy as a viable form of cancer treatment has provided a
new platform for growth, innovation and a powerful tool for fighting cancers by
harnessing the innate prowess of the immune system. One area of advancement in
the immunotherapy originates from the ability to enhance the immune system’s
natural abilities with the addition of adjuvants and stimuli through vaccination. In
this study, we sought to explore the immunogenic potential of vaccination of both
ex-vivo primed dendritic cells as well as vaccinations aimed at targeting and
activating dendritic cells in-vivo.
Several different factors have been discussed in the examination of dendritic
cell vaccinations. These factors include ex-vivo versus in-vivo targeting of dendritic
cells, antigen selection, adjuvant selecting, antigen-carrier options and DC targeting
strategies. In order to create an effective vaccine that can stimulate a lasting and
targeted anti-tumor response, all of the components of a vaccination must be
considered not only for their ability to function collaboratively, but also to work for
the individual cancer scenario. Effectively, this means that there is not one perfect
cure all for cancer, however, there is the potential for different vaccines to work
productively for particular cancers and at different stages of cancer progression.
The individual project presented in this article addresses some of the factors
that can contribute to the success of a dendritic cell-based vaccination strategy. The
adjuvants selected for vaccination can play unique and critical roles in priming
dendritic cells for antigen presentation and subsequent T-cell activation and

differentiation. In the current project, the adjuvants I selected played a crucial role
in promoting dendritic cells to produce surface cell receptors critical to antigen
presentation and co-stimulation of T-cells. In contrast, the specific antigen selected
had much less of an impact on cell surface receptors, but still had a tremendous
effect on inducing cytokine secretion by the DCs. These unique functions of the
adjuvants and antigen demonstrate their interdependence and the importance of
creating a balanced vaccine that contributes sufficiently to both aspects of DC
activation and functionality.
Overall, vaccinations aimed at inducing dendritic cell responses that have the
ability to direct targeted, tumor specific immune attacks, have the potential to
become not just one type of cancer therapy, but one of the most effective and nontoxic cancer eradication methods. Dendritic cell vaccinations are customizable,
workable and largely innocuous. These vaccinations are geared at wielding the preexistent defense mechanisms and functions of the immune system and enabling
them to recognize cancer cells as malignancies. In addition to a prompt immune
response, vaccinations have the potential to induce lasting immunity, which serves
to prevent recurrent tumor growth. With further refinement and testing,
immunotherapy through vaccination has the capacity to become a powerful tool in
cancer therapy.
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